1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)- has been researched along with Cirrhoses, Experimental Liver in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukui, H; Kojima, H; Takaya, A; Tsujimoto, T; Uemura, M; Yamao, J | 1 |
1 other study(ies) available for 1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)- and Cirrhoses, Experimental Liver
| Article | Year |
|---|---|
Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance.
Topics: Animals; Arteries; Endothelin Receptor Antagonists; Endothelin-1; Indans; Liver; Liver Cirrhosis, Experimental; Male; Portal Pressure; Portal Vein; Rats; Rats, Sprague-Dawley; Renal Circulation; Vascular Resistance | 2000 |